No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AUPH240517C5000
- 0.25
- +0.03+13.64%
15min DelayClose May 8 15:59 ET
0.25High0.25Low
0.25Open0.22Pre Close10 Volume1.46K Open Interest5.00Strike Price250.00Turnover41.59%IV1.46%PremiumMay 17, 2024Expiry Date0.15Intrinsic Value100Multiplier8DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.6930Delta1.0428Gamma22.89Leverage Ratio-0.0072Theta0.0008Rho15.86Eff Leverage0.0028Vega
Intraday
- 5D
- 1D
News
Express News | Shareholder Lucien Selce: Aurinia Should Immediately Link Management's Compensation to Fulfilling Quantitative Revenue Goals Set by Independent Board
Express News | Shareholder Lucien Selce: Aurinia Should Immediately Restructure Board and Reduce Its Size From Nine Directors to Five Directors
Express News | Shareholder Lucien Selce: Aurinia Board's Size Should Be Reduced to Ensure Efficiency and Cost-Effectiveness
Express News | Shareholder Lucien Selce: Believe Composition of Board, Excessive Number of Directors Sitting on It Holding Aurinia Back From Achieving Full Potential
Express News | Lucien Selce Issued Letter to Aurinia Shareholders
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference May 7, 2024 • 6:00 am EDT Download as PDF ROCKVILLE, Md. & EDMONTON, Alberta--(
Comments
AUPH been getting some pops last couple days. Here are the levels to watch.
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US$
Larger Image: tradingview.com...
$Aurinia Pharmaceuticals(AUPH.US$
$Aurinia Pharmaceuticals(AUPH.US$
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...
NEWS
The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program
The FDA has approved an updated label for LUPKYNIS, a drug by Aurinia Pharmaceuticals (NASDAQ: AUPH), including long-term data from the AURORA Clinical Program, showing sustained complete renal response through three years. The label now indicates that monthly kidney function assessment is no longer required af...
The company's missed forecasts and lack of positive strategic review results may dampen investor sentiment. However, cost savings from discontinuing early-stage drugs and reducing staff, along with share buybacks, could offset some negativity.
Recent insider selling activity and lack of trades in the last quarter at Aurinia Pharmaceuticals may concern investors. However, modest insider ownership could suggest alignment between management and smaller shareholders.
Shareholders may not be comfortable amid potentially dimmer future expectations for the company, possibly causing the lower P/S ratio. A shift in the company's fortunes would be required to justify an increase in the P/S.
Read more